他莫昔芬治疗包裹性腹膜硬化症的研究进展
Research progress in tamoxifen in treatment of encapsulating peritoneal sclerosis
康达贤 1孙丽萍 1张欣洲1
作者信息
- 1. 518020 深圳,暨南大学第二临床医学院
- 折叠
摘要
包裹性腹膜硬化症(EPS)是长期腹膜透析患者的一种少见且严重的并发症,主要见于长期腹膜透析和有反复、严重腹膜透析相关性腹膜炎(PDAP)病史者.EPS早期诊断困难,预后差、病死率高,其发病机制仍未完全清楚,目前缺乏理想的预防和治疗方案.他莫昔芬是一种选择性雌激素受体调节剂,目前可应用于治疗乳腺癌、卵巢癌及某些以纤维化病变为特征的疾病.有研究表明他莫昔芬也可用于治疗EPS.该文对EPS及他莫昔芬治疗EPS的相关研究进展进行了系统综述.
Abstract
Encapsulating peritoneal sclerosis(EPS)is a rare and serious complication in patients with long-term peritoneal dialysis and a history of recurrent and severe peritoneal dialysis-associated peritonitis(PDAP).Early diagnosis of EPS is difficult,clinical prognosis is poor,and the fatality rate is high.The pathogenesis of EPS is still not fully understood,and ideal prevention and treatment regimens are still lacking.Tamoxifen,a selective estrogen receptor modulator,is currently used in the treatment of breast cancer,ovarian cancer and some diseases characterized by fibrotic lesions.Studies have shown that tamoxifen can also be used to treat EPS.In this article,research progress in EPS and tamoxifen in the treatment of EPS was systematically reviewed.
关键词
他莫昔芬/包裹性腹膜硬化症/选择性雌激素受体调节剂/腹膜透析/治疗Key words
Tamoxifen/Encapsulating peritoneal sclerosis/Selective estrogen receptor modulators/Peritoneal dialysis/Therapy引用本文复制引用
基金项目
广东省高水平临床重点专科基金(深圳市配套建设经费)项目(SZGSP001)
深圳市科创委可持续发展专项(KCXFZ20201221173612034)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据